NGL Fine-Chem Q2FY27 Results: Strong Operating Performance Driven by Volume Growth
NGL Fine Chem Ltd · Investor Presentation · 11 Nov 2026, 4:07 am
NGL Fine-Chem Q2FY27 Results: Strong Operating Performance Driven by Volume Growth NGL Fine-Chem delivered strong Q2FY27 revenue from operations of ₹158.71 Cr, surging 31.97% YoY and 14.05% QoQ, driven by robust volume demand. EBITDA grew 63.52% YoY to ₹28.06 Cr with margins expanding 341 bps YoY to 17.68%. PAT rose 68.74% YoY to ₹16.25 Cr. Animal API contributed 95% of revenues. The company commissioned its Phase-II facility (₹220.72 Cr capex), targeting 30%–40% capacity utilization over 2–3 quarters, while advancing European registration transfers and nine US Veterinary Master File filings for impending USFDA inspection.
Original exchange filing (PDF)
More announcements from NGL Fine Chem Ltd
- Audio Recording of Earning Conference Call Q2 & H1 FY27. · 13 Nov 2026
- Outcome of Board Meeting Dates November 06, 2026. · 07 Nov 2026
- Outcome of the Board Meeting Dates November 06, 2026 · 07 Nov 2026
- NGL Fine-Chem Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 07 Nov 2026
- Outcome of Board Meeting · 07 Nov 2026
- Intimation of schedule of Earning Conference Call to discuss Q2 & H1 FY27 Results · 12 Nov 2026
- NGL FINE-CHEM LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 06 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 06 Nov 2026
